Enliven Therapeutics (NASDAQ:ELVN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Enliven Therapeutics (NASDAQ:ELVN) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other brokerages have also recently weighed in on ELVN. Mizuho boosted their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Stifel Nicolaus raised their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday. JonesTrading lifted their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Guggenheim decreased their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group increased their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $72.67.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $60.46 on Friday. The stock’s fifty day moving average is $48.62 and its two-hundred day moving average is $39.68. The firm has a market capitalization of $3.68 billion, a P/E ratio of -36.20 and a beta of 0.27. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts forecast that Enliven Therapeutics will post -1.67 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the sale, the director directly owned 87,373 shares in the company, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $221,255,000. Vestal Point Capital LP raised its position in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Siren L.L.C. purchased a new stake in Enliven Therapeutics in the first quarter valued at approximately $29,252,000. Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics during the first quarter worth $23,007,000. Finally, TCG Crossover Management LLC acquired a new position in Enliven Therapeutics during the second quarter worth $9,990,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.